华邦健康：仿制药集采是国家进行医保控费、推动药品质量提升的大趋势，但目前对公司而言影响相对有限

Core Viewpoint - The announcement from Huabang Health indicates that while the national collection of generic drugs is a trend aimed at controlling medical insurance costs and improving drug quality, its current impact on the company is relatively limited [1] Summary by Relevant Categories Impact of Generic Drug Collection - The progress of including topical drugs in the collection is slower compared to other medications, providing the company with a time window for further layout and adjustments [1] - The company is actively promoting the consistency evaluation of generic drugs while continuously controlling production costs and improving production processes, laying a solid foundation for participation in the collection [1] Product and Market Strategy - The company has a comprehensive pipeline in the dermatology field with numerous products, forming a product matrix targeting various diseases. After drugs are included in the collection, the company can mitigate impacts by promoting alternative drugs [1] - The company is not solely focused on chemical generics but has established a full industry chain around "big skin," including raw materials, formulations, functional skincare products, pan-skin health management, and medical services. Generic drugs are just one part of the business [1] Market Development and Innovation - The collection primarily targets the prescription market, and the company is leveraging the current time window to vigorously develop the broad market, enhancing terminal coverage through brand chain pharmacies and e-commerce channels to increase retail market share [1] - In addition to existing drugs, the company is actively advancing new drug research and development, rolling out 3-5 new projects annually to ensure a continuous stream of new products [1]